Microglial cell origin and phenotypes in health and disease

Nature Reviews Immunology

Volumn 11, Issue 11, 2011, Pages 775-787

  Saijo, Kaoru ^a   Glass, Christopher K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CD11B ANTIGEN; CD14 ANTIGEN; CD200 ANTIGEN; CD200 RECEPTOR; CD22 ANTIGEN; CD45 ANTIGEN; CD47 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; COLONY STIMULATING FACTOR 1; CRYOPYRIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE 14; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PRESENILIN 1; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RUNX1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIGEN EXPRESSION; ASTROCYTE; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL LINEAGE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; GLIOMA; HEALTH; HIV ASSOCIATED DEMENTIA; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; MICROGLIA; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARABIOSIS; PARKINSON DISEASE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEADY STATE; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

BRAIN; CELL LINEAGE; GENE EXPRESSION; HUMANS; MICROGLIA; MYELOID CELLS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PHENOTYPE; SPINAL CORD;

EID: 80355143546     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3086     Document Type: Review

References (121)

1. Kettenmann, H., Hanisch, U. K., Noda, M. & Verkhratsky, A. Physiology of microglia. Physiol. Rev. 91, 461-553 (2011).
2. Ransohoff, R. M. & Perry, V. H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119-145 (2009).
3. Lawson, L. J., Perry, V. H., Dri, P. & Gordon, S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151-170 (1990).
4. Perry, V. H. & Gordon, S. Macrophages and the nervous system. Int. Rev. Cytol. 125, 203-244 (1991).
5. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C. & Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934 (2010).
6. Perry, V. H., Nicoll, J. A. & Holmes, C. Microglia in neurodegenerative disease. Nature Rev. Neurol. 6, 193-201 (2010).
7. Rio-Hortega, P. D. in Cytology and Cellular Pathology of the Nervous System (ed. Penfield, W.) 482-534 (P.B. Hoeber, Inc., New York, 1932).
8. MacDonald, K. P. et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue-and tumor-associated macrophages but does not inhibit inflammation. Blood 116, 3955-3963 (2010).
9. Beers, D. R. et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 103, 16021-16026 (2006).
10. Eglitis, M. A. & Mezey, E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc. Natl Acad. Sci. USA 94, 4080-4085 (1997).
11. Priller, J. et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nature Med. 7, 1356-1361 (2001).
12. Hickey, W. F. & Kimura, H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239, 290-292 (1988).
13. Ransohoff, R. M. Microgliosis: the questions shape the answers. Nature Neurosci. 10, 1507-1509 (2007).
14. Tanaka, R. et al. Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience 117, 531-539 (2003).
15. Mildner, A. et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31, 11159-11171 (2011).
16. Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nature Neurosci. 10, 1538-1543 (2007).
17. Mildner, A. et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nature Neurosci. 10, 1544-1553 (2007).
18. Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841-845 (2010).
19. Samokhvalov, I. M., Samokhvalova, N. I. & Nishikawa, S. Cell tracing shows the contribution of the yolk sac to adult haematopoiesis. Nature 446, 1056-1061 (2007).
20. King, I. L., Dickendesher, T. L. & Segal, B. M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113, 3190-3197 (2009).
21. Mildner, A. et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132, 2487-2500 (2009).
22. Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M. & Rossi, F. M. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nature Neurosci. 14, 1142-1149 (2011).
23. Fellner, L., Jellinger, K. A., Wenning, G. K. & Stefanova, N. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol. 121, 675-693 (2011).
24. Reitz, C., Brayne, C. & Mayeux, R. Epidemiology of Alzheimer disease. Nature Rev. Neurol. 7, 137-152 (2011).
25. Lawson, L. J., Perry, V. H. & Gordon, S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48, 405-415 (1992).
26. Chorro, L. et al. Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network. J. Exp. Med. 206, 3089-3100 (2009).
27. Polazzi, E. & Monti, B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog. Neurobiol. 92, 293-315 (2010).
28. Dimos, J. T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218-1221 (2008).
29. Park, I. H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877-886 (2008).
30. Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations. Cell 416, 318-331 (2011).
31. Beutner, C., Roy, K., Linnartz, B., Napoli, I. & Neumann, H. Generation of microglial cells from mouse embryonic stem cells. Nature Protoc. 5, 1481-1494 (2010).
32. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
33. de Haas, A. H., Boddeke, H. W. & Biber, K. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 56, 888-894 (2008).
34. Martinez, F. O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483 (2009).
35. Odegaard, J. I. & Chawla, A. Alternative macrophage activation and metabolism. Annu. Rev. Pathol. 6, 275-297 (2011).
36. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219-246 (2010).
37. Sica, A. et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349-355 (2008).
38. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005).
39. Bessis, A., Bechade, C., Bernard, D. & Roumier, A. Microglial control of neuronal death and synaptic properties. Glia 55, 233-238 (2007).
40. Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456-1458 (2011).
41. Sierra, A. et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 7, 483-495 (2010).
42. Cardona, A. E. et al. Control of microglial neurotoxicity by the fractalkine receptor. Nature Neurosci. 9, 917-924 (2006).
43. Fuhrmann, M. et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nature Neurosci. 13, 411-413 (2010).
44. Ransohoff, R. M. & Cardona, A. E. The myeloid cells of the central nervous system parenchyma. Nature 468, 253-262 (2010).
45. Turnbull, I. R. et al. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177, 3520-3524 (2006).
46. Hamerman, J. A. et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J. Immunol. 177, 2051-2055 (2006).
47. Paloneva, J. et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71, 656-662 (2002).
48. Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nature Rev. Immunol. 10, 826-837 (2010).
49. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
50. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51 (2010).
51. Penfield, W. Microglia and the process of phagocytosis in gliomas. Am. J. Pathol. 1, 77-90.15 (1925).
52. Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R. & Kettenmann, H. The brain tumor microenvironment. Glia 59, 1169-1180 (2011).
53. Ghosh, A. & Chaudhuri, S. Microglial action in glioma: a boon turns bane. Immunol. Lett. 131, 3-9 (2010).
54. Qiu, B. et al. IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas. Mol. Biol. Rep. 38, 3585-3591 (2011).
55. Wu, A. et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 12, 1113-1125 (2010).
56. Black, K. L., Chen, K., Becker, D. P. & Merrill, J. E. Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J. Neurosurg. 77, 120-126 (1992).
57. Wei, J. et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 16, 461-473 (2010).
58. Zou, J. P. et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J. Immunol. 162, 4882-4892 (1999).
59. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
60. Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499-4506 (2009).
61. Yang, I., Han, S. J., Kaur, G., Crane, C. & Parsa, A. T. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 17, 6-10 (2010).
62. Markovic, D. S., Glass, R., Synowitz, M., Rooijen, N. & Kettenmann, H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J. Neuropathol. Exp. Neurol. 64, 754-762 (2005).
63. Markovic, D. S. et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl Acad. Sci. USA 106, 12530-12535 (2009).
64. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nature Neurosci. 8, 752-758 (2005).
65. O'Keefe, G. M., Nguyen, V. T. & Benveniste, E. N. Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: implications in neurological diseases. J. Neurovirol. 8, 496-512 (2002).
66. Saijo, K. et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137, 47-59 (2009).
67. Bhaskar, K. et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68, 19-31 (2010).
68. Bauman, D. R. et al. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc. Natl Acad. Sci. USA 106, 16764-16769 (2009).
69. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999).
70. Xu, J. et al. Extracellular histones are major mediators of death in sepsis. Nature Med. 15, 1318-1321 (2009).
71. Burguillos, M. A. et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 472, 319-324 (2011).
72. Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nature Immunol. 9, 857-865 (2008).
73. Salminen, A., Ojala, J., Suuronen, T., Kaarniranta, K. & Kauppinen, A. Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology. J. Cell. Mol. Med. 12, 2255-2262 (2008).
74. Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R. & Coyle, A. J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367-388 (2010).
75. Inoue, K. Purinergic systems in microglia. Cell. Mol. Life Sci. 65, 3074-3080 (2008).
76. Junger, W. G. Immune cell regulation by autocrine purinergic signalling. Nature Rev. Immunol. 11, 201-212 (2011).
77. Koizumi, S. et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446, 1091-1095 (2007).
78. Volontiota;, C., Apolloni, S., Carri, M. T. & D'Ambrosi, N. ALS: focus on purinergic signalling. Pharmacol. Ther. 132, 111-122 (2011).
79. Erlandsson Harris, H. & Andersson, U. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur. J. Immunol. 34, 1503-1512 (2004).
80. Yan, S. D., Bierhaus, A., Nawroth, P. P. & Stern, D. M. RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation? J. Alzheimers Dis. 16, 833-843 (2009).
81. Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nature Immunol. 12, 204-212 (2011).
82. Goldfine, A. B., Fonseca, V. & Shoelson, S. E. Therapeutic approaches to target inflammation in type 2 diabetes. Clin. Chem. 57, 162-167 (2011).
83. Saijo, K., Crotti, A. & Glass, C. K. Nuclear receptors, inflammation, and neurodegenerative diseases. Adv. Immunol. 106, 21-59 (2010).
84. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
85. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8, 382-397 (2009).
86. Dutta, G., Zhang, P. & Liu, B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol. 22, 453-464 (2008).
87. Roodveldt, C., Christodoulou, J. & Dobson, C. M. Immunological features of α-synuclein in Parkinson's disease. J. Cell. Mol. Med. 12, 1820-1829 (2008).
88. Landreth, G. E. & Reed-Geaghan, E. G. Toll-like receptors in Alzheimer's disease. Curr. Top. Microbiol. Immunol. 336, 137-153 (2009).
89. Daborg, J. et al. Association of the RAGE G82S polymorphism with Alzheimer's disease. J. Neural Transm. 117, 861-867 (2010).
90. Li, K. et al. Association between the RAGE G82S polymorphism and Alzheimer's disease. J. Neural Transm. 117, 97-104 (2010).
91. Lee, C. Y. & Landreth, G. E. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 117, 949-960 (2010).
92. Sokolowski, J. D. & Mandell, J. W. Phagocytic clearance in neurodegeneration. Am. J. Pathol. 178, 1416-1428 (2011).
93. Verghese, P. B., Castellano, J. M. & Holtzman, D. M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10, 241-252 (2011).
94. Kamer, A. R. et al. Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement. 4, 242-250 (2008).
95. Finch, C. E. & Morgan, T. E. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr. Alzheimer Res. 4, 185-189 (2007).
96. Granic, I., Dolga, A. M., Nijholt, I. M., van Dijk, G. & Eisel, U. L. Inflammation and NF-κB in Alzheimer's disease and diabetes. J. Alzheimers Dis. 16, 809-821 (2009).
97. Jones, A., Kulozik, P., Ostertag, A. & Herzig, S. Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J. Alzheimers Dis. 16, 787-808 (2009).
98. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genet. 43, 429-435 (2011).
99. Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genet. 41, 1094-1099 (2009).
100. Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genet. 43, 436-441 (2011).
101. Grathwohl, S. A. et al. Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia. Nature Neurosci. 12, 1361-1363 (2009).
102. Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141-155 (2011).
103. Rackstraw, S. HIV-related neurocognitive impairment-a review. Psychol. Health Med. 16, 548-563 (2011).
104. Strazza, M., Pirrone, V., Wigdahl, B. & Nonnemacher, M. R. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res. 1399, 96-115 (2011).
105. Gannon, P., Khan, M. Z. & Kolson, D. L. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr. Opin. Neurol. 24, 275-283 (2011).
106. Yadav, A. & Collman, R. G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune Pharmacol. 4, 430-447 (2009).
107. Liner, K. J., Ro, M. J. & Robertson, K. R. HIV, antiretroviral therapies, and the brain. Curr. HIV/AIDS Rep. 7, 85-91 (2010).
108. Hult, B., Chana, G., Masliah, E. & Everall, I. Neurobiology of HIV. Int. Rev. Psychiatry 20, 3-13 (2008).
109. Saijo, K., Collier, J. G., Li, A. C., Katzenellenbogen, J. A. & Glass, C. K. An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 145, 584-595 (2011).
110. Jellinck, P. H. et al. Dehydroepiandrosterone (DHEA) metabolism in the brain: identification by liquid chromatography/mass spectrometry of the δ-4-isomer of DHEA and related steroids formed from androstenedione by mouse BV2 microglia. J. Steroid Biochem. Mol. Biol. 98, 41-47 (2006).
111. Kuiper, G. G. et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870 (1997).
112. Heiman, M. et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 135, 738-748 (2008).
113. Blasius, A. L. & Beutler, B. Intracellular Toll-like receptors. Immunity 32, 305-315 (2010).
114. Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650 (2011).
115. Brikos, C. & O'Neill, L. A. Signalling of Toll-like receptors. Handb. Exp. Pharmacol. 183, 21-50 (2008).
116. Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16-34 (2011).
117. Barbalat, R., Ewald, S. E., Mouchess, M. L. & Barton, G. M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185-214 (2011).
118. Davis, B. K., Wen, H. & Ting, J. P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 29, 707-735 (2011).
119. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
120. Jin, C. & Flavell, R. A. Molecular mechanism of NLRP3 inflammasome activation. J. Clin. Immunol. 30, 628-631 (2010).
121. Bauernfeind, F. et al. Inflammasomes: current understanding and open questions. Cell. Mol. Life Sci. 68, 765-783 (2011).